![]() ![]() In January 2022, Illumina collaborated with National Cancer Center Japan for an international joint research project that will utilize Illumina's high-throughput DNA sequencing to assess the blood-based genomic profile and clinical information of patients living with nasopharyngeal carcinoma. The increasing prevalence of various types of cancer globally, the rising public awareness about the importance of early cancer diagnosis, and technological developments in diagnostic systems are the major factors driving the market. Per Reports and Data, the global cancer diagnostics market size was $163.84 billion in 2020 and is expected to reach $268.10 billion by 2028, at a CAGR of 6.3%. Point32Health, the combined organization of Harvard Pilgrim Health Care and Tufts Health Plan, delivers innovative medical advances that focus on improving the health and wellness of its colleagues and members. When cancer is detected, the Galleri MCED test predicted the origin of the cancer signal with high accuracy across multiple cancer types. Per a clinical study, the Galleri test demonstrated the ability to detect more than 50 types of cancer. It is worth mentioning that, according to the American Cancer Society, more than 600,000 people died from cancer last year in the United States. Notably, Point32Health is the first commercial health plan in the United States to collaborate with GRAIL on Galleri, which has the potential to be a game-changing screening tool that could be life-saving for people in the early detection of cancer. ILMN recently announced that its wholly-owned subsidiary, GRAIL, entered into an agreement with Point32Health to partner on a two-phased pilot of Galleri multi-cancer early detection blood (MCED) test.
0 Comments
Leave a Reply. |